These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 1375331)

  • 21. Activated ras oncogene and specifically acquired resistance to cisplatin in human mammary epithelial cells: induction of DNA cross-links and their repair.
    Levy E; Baroche C; Barret JM; Alapetite C; Salles B; Averbeck D; Moustacchi E
    Carcinogenesis; 1994 May; 15(5):845-50. PubMed ID: 8200085
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines.
    Mamenta EL; Poma EE; Kaufmann WK; Delmastro DA; Grady HL; Chaney SG
    Cancer Res; 1994 Jul; 54(13):3500-5. PubMed ID: 8012973
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
    O'Neill CF; Koberle B; Masters JR; Kelland LR
    Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alterations of DNA repair in melanoma cell lines resistant to cisplatin, fotemustine, or etoposide.
    Rünger TM; Emmert S; Schadendorf D; Diem C; Epe B; Hellfritsch D
    J Invest Dermatol; 2000 Jan; 114(1):34-9. PubMed ID: 10620112
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhanced repair of a cisplatin-damaged reporter chloramphenicol-O-acetyltransferase gene and altered activities of DNA polymerases alpha and beta, and DNA ligase in cells of a human malignant glioma following in vivo cisplatin therapy.
    Ali-Osman F; Berger MS; Rairkar A; Stein DE
    J Cell Biochem; 1994 Jan; 54(1):11-9. PubMed ID: 8126081
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Decreased cisplatin/DNA adduct formation is associated with cisplatin resistance in human head and neck cancer cell lines.
    Yang Z; Faustino PJ; Andrews PA; Monastra R; Rasmussen AA; Ellison CD; Cullen KJ
    Cancer Chemother Pharmacol; 2000; 46(4):255-62. PubMed ID: 11052622
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene.
    Yu JJ; Lee KB; Mu C; Li Q; Abernathy TV; Bostick-Bruton F; Reed E
    Int J Oncol; 2000 Mar; 16(3):555-60. PubMed ID: 10675489
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced excision repair of DNA damage due to cis-diamminedichloroplatinum(II) in resistant cervix carcinoma HeLa cells.
    Chao CC
    Eur J Pharmacol; 1994 Aug; 268(3):347-55. PubMed ID: 7805758
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair.
    Kudo K; Gavin E; Das S; Amable L; Shevde LA; Reed E
    Oncogene; 2012 Nov; 31(44):4718-24. PubMed ID: 22266871
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of novel plasmid constructs to demonstrate fludarabine triphosphate inhibition of nucleotide excision repair of a site-specific 1,2-d(GpG) intrastrand cisplatin adduct.
    Li MJ; Yang LY
    Int J Oncol; 1999 Dec; 15(6):1177-83. PubMed ID: 10568825
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Elevated DNA repair capacity is associated with intrinsic resistance of lung cancer to chemotherapy.
    Zeng-Rong N; Paterson J; Alpert L; Tsao MS; Viallet J; Alaoui-Jamali MA
    Cancer Res; 1995 Nov; 55(21):4760-4. PubMed ID: 7585500
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decreased accumulation as a mechanism of resistance to cis-diamminedichloroplatinum(II) in cervix carcinoma HeLa cells: relation to DNA repair.
    Chao CC
    Mol Pharmacol; 1994 Jun; 45(6):1137-44. PubMed ID: 8022407
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells.
    Johnson SW; Swiggard PA; Handel LM; Brennan JM; Godwin AK; Ozols RF; Hamilton TC
    Cancer Res; 1994 Nov; 54(22):5911-6. PubMed ID: 7954422
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of glutathione in resistance to cisplatin in a human small cell lung cancer cell line.
    Meijer C; Mulder NH; Hospers GA; Uges DR; de Vries EG
    Br J Cancer; 1990 Jul; 62(1):72-7. PubMed ID: 2390486
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin.
    Mellish KJ; Kelland LR; Harrap KR
    Br J Cancer; 1993 Aug; 68(2):240-50. PubMed ID: 8347478
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resistance mechanisms following cisplatin and oxaliplatin treatment of the human teratocarcinoma cell line 2102EP.
    Rennicke A; Voigt W; Mueller T; Fruehauf A; Schmoll HJ; Beyer C; Dempke W
    Anticancer Res; 2005; 25(2A):1147-55. PubMed ID: 15868958
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fludarabine-mediated repair inhibition of cisplatin-induced DNA lesions in human chronic myelogenous leukemia-blast crisis K562 cells: induction of synergistic cytotoxicity independent of reversal of apoptosis resistance.
    Li L; Keating MJ; Plunkett W; Yang LY
    Mol Pharmacol; 1997 Nov; 52(5):798-806. PubMed ID: 9351970
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Decreased drug accumulation and increased tolerance to DNA damage in tumor cells with a low level of cisplatin resistance.
    Lanzi C; Perego P; Supino R; Romanelli S; Pensa T; Carenini N; Viano I; Colangelo D; Leone R; Apostoli P; Cassinelli G; Gambetta RA; Zunino F
    Biochem Pharmacol; 1998 Apr; 55(8):1247-54. PubMed ID: 9719480
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin.
    Lau DH; Lewis AD; Ehsan MN; Sikic BI
    Cancer Res; 1991 Oct; 51(19):5181-7. PubMed ID: 1717140
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of resistance mechanisms to cis-diamminedichloroplatinum(II) in three sublines of the CC531 colon adenocarcinoma cell line in vitro.
    Oldenburg J; Begg AC; van Vugt MJ; Ruevekamp M; Schornagel JH; Pinedo HM; Los G
    Cancer Res; 1994 Jan; 54(2):487-93. PubMed ID: 8275486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.